The mental health track has ushered in the wind, and domestic pharmaceutical companies are vigorously layout

Rapid social change may have caused an overall increase in people's psychological stress and stress levels, and with the continuous backlog of negative emotions, psychological problems such as depression and anxiety are now emerging
.
Affected by this, in recent years, mental health diseases are generally on the rise, and the entire industry market has maintained a continuous growth trend
.
According to the 2020 Global Health Institute's Defining the Mental Health Economy report, the global mental health market has reached $121 billion
.
In China, according to industry estimates, the market size of the mental health field has also reached about 300 billion yuan
.
In recent years, many practitioners in this field are beginning to explore relevant solutions to solve the current pain points
in the industry.
From the current point of view, for enterprises involved in the mental health industry, their playing styles are different, some are deeply engaged in vertical segmentation, and some are in multi-point layout
.
Among them, due to mental illness, long-term medication and continuous psychological counseling and psychotherapy
are required.
Therefore, in recent years, it can be clearly found that pharmaceutical companies are constantly increasing their layout
in the mental health track.
Among them, the attention of pharmaceutical companies in mental diseases such as depression, schizophrenia and schizoaffective disorder has been increasing, so the research and development of related drugs is also accelerating
.
It is reported that under the continuous efforts of pharmaceutical companies, some companies have begun to usher in good news
.
For example, on November 3, Luye Pharmaceutical announced that its self-developed Class 1 innovative drug Toludi Lafaxine hydrochloride sustained-release tablets (trade name: Ruoxinlin) was officially approved for marketing for the treatment of depression
.
According to clinical studies, Ruoxinlin can comprehensively and stably treat depression, significantly improve anxiety state, block/fatigue symptoms, anhedonia and cognitive ability, promote the recovery of social functions, and has good safety and tolerability, does not cause drowsiness, does not affect sexual function, weight and lipid metabolism, and is expected to bring more treatment options
to domestic patients with depression 。 Later, on November 21, Luye Pharmaceutical announced that the key clinical trial of paliprazone palmitate sustained-release suspension injection (LY 03010), a new drug developed by the Group for the treatment of schizophrenia and schizoaffective disorder, has completed data analysis, and the results show that the preset endpoint has been reached, and based on the results of communication with the FDA in the early stage, LY 03010 plans to submit a new drug application (NDA) to the US Food and Drug Administration (FDA) through the 505 (b) (2) route
。 In September, Fosun Pharma also announced that the application for registration of aripiprazole oral solution developed by its holding subsidiary Fosun Pharmaceutical Industry and its holding subsidiary Jinzhou Aohong Pharmaceutical was accepted by the State Food and Drug Administration for the treatment of
schizophrenia in adults and adolescents over 15 years old.
The new drug is a chemical independently developed by Fosun Pharma and is intended to be mainly used for the treatment of
schizophrenia.
As of July 2022, the cumulative R&D investment for this new drug is approximately RMB 3.
71 million (unaudited).

.
.
.
.
.
.
In addition to the emergence of related drugs, the financing of the domestic mental health industry is also very hot
.
Data show that since 2021, a total of 24 investments and financings have occurred in the field of mental health, with a cumulative investment and financing amount of more than 1.
5 billion yuan
.
For example, in September 2021, ByteDance led the 200 million yuan C round of financing of the mental health digital service platform Good Mood, breaking the single financing record
of the domestic mental health track at that time.
In addition, the AI psychological service technology company Westlake Xinchen even raised nearly ten million dollars in the angel round alone.
.
.
At present, the financing projects of the mental health industry have involved multiple links, including services, software platforms, and technology research and development, as well as subdivided vertical fields, and the investment distribution has been quite extensive
.
The industry believes that with the continuous increase of the layout of enterprises, patients will usher in more choices
in mental health treatment.
Among them, the psychiatric drug market is huge, if pharmaceutical companies continue to focus on this area, it is expected to develop more products around the unmet treatment needs of more patients, so as to continuously improve the effectiveness, safety and compliance of patients
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.